An interventional study of BodyGuardian Mini Plus in Torsades de Pointe Caused by Drug and Long QT Syndrome, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Diagnostic
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Long QT Syndrome with a site in United States — 7 open to participants now, 7 under way, 1 of them phase 3. Long QT Syndrome · United States.
Among the 44 studies in Long QT Syndrome with a site in United States, this one is the 9th largest by planned enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 with no phase, and was the 36th registered.
101 studies on the registry are indexed under Long QT Syndrome; 20 are open to participants now.
Browse Long QT Syndrome studies →7 of the 44 studies in Long QT Syndrome with a site in United States are open now. Recruiting first, the newest first:
Thryv Therapeutics, Inc. · Sites in United States
Ages 15+
University of Maryland, Baltimore · Sites in United States
Ages 18+
Medical College of Wisconsin · Sites in United States
Ages 18+ · Women only
Mayo Clinic · Sites in United States
Ages 18–50
Peerbridge Health, Inc · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Long QT Syndrome studies recruiting now, 10 (71%) set no upper age limit and 3 (21%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 4 · Phase 3 2 · Phase 4 5
First in 1985; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 45 across 46 interventional studies indexed under Long QT Syndrome.
Median enrollment 44 across the 28 interventional studies, 96 across the 16 observational. Of the 33 that completed or were terminated, 14 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 44 have an industry lead sponsor. The 10 most frequent:
Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
Washington University School of Medicine has 1 study filed under Long QT Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Long QT Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07277582Phase 3Thryv Therapeutics, Inc.Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3) | 2027-06-30 |
| NCT04336644Washington University School of MedicineContinuous Versus Intermittent cARdiac Electrical moNitorinG | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Long QT Syndrome with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to validate the continuous patch monitoring system to evaluate cardiac arrhythmias in patients receiving drugs that can cause cardiac complications and compare the continuous patch system with standard electrocardiograms (ECGs).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
-Participants will receive standard of care treatment with either arsenic trioxide, ribociclib, or capecitabine. They will have continuous patch monitor system (BodyGuardian Mini Plus) applied on or prior to the first day of therapy and will receive at least 5 ECGs for comparison during the first 30 days of treatment.
Device: BodyGuardian Mini Plus
The BodyGuardian Mini Plus attaches to the upper chest of the patient through the use of an adhesive patch. ECG tracings are recorded continuously and sent to the linked smartphone and subsequently to a cloud server.
Also known as: Continuous patch monitoring system
This study also gives RibociclibStudies of RibociclibRibociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Comparison of blinded, manual measurements of the ECGs to the patch monitor tracings as measured by the Bland-Altman Plot
* The Bland Altman plot provides a graphical method to compare the question of interest, namely that the measurements derived from the patch monitor are accurate in relation to the gold standard of the ECG. * Each QT measured from the tracing will be plotted against the difference in QT between the tracing and the 12-lead ECG. The acceptable difference between measurement techniques will be set at 5 ms (primary, strict threshold based on FDA recommendations) with a clinically acceptable difference of 15 ms (based on known variability in 12-lead ECG recordings).
Time frame: Through Day 30
Frequency of major arrhythmia occurrence
* The QT interval will be assessed every 4 hours for the first 5 days and then every 8 hours thereafter
Time frame: Through Day 30
Trajectories of QT prolongation
* Will assess the QT interval every four hours for five days after drug initiation and after five days, the QTc will be assessed every 8 hours * With this data, the investigators will plot the QTc interval (Fridericia correction) over time and determine the time of expected peak effect. Outliers will be reviewed and verified manually.
Time frame: Through day 30
Plan to share: Yes — Data will be shared with other researchers. They may be doing research in areas similar to this research or in other unrelated areas. These researchers may be at Washington University, at other research centers and institutions, or industry sponsors of research. We may also share your research data with large data repositories (a repository is a database of information) for broad sharing with the research community. If your individual research data is placed in one of these repositories only qualified researchers, who have received prior approval from individuals that monitor the use of the data, will be able to look at your information.
Supporting information: Study protocol
Time frame: Immediately following publication. No end date.
Access criteria: Please email any proposals to jdmitchell@wustl.edu.
Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.
Of 15 interventional studies with no phase under Long QT Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 37 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Washington University School of Medicine →